Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Wilms Tumor 8Rhabdoid Tumor 7Osteosarcoma 7Neuroblastoma 7Medulloblastoma 7Lymphoma, Non-Hodgkin 7Hepatoblastoma 7Glioma 7Sarcoma 6Rhabdomyosarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Histiocytosis, Langerhans-Cell 6Ependymoma 6Central Nervous System Neoplasms 6Sarcoma, Ewing 4Multiple Myeloma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Lymphoma, B-Cell 3Lung Neoplasms 3Colorectal Neoplasms 3Burkitt Lymphoma 3Rectal Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Nasopharyngeal Carcinoma 2Lymphoma, Large B-Cell, Diffuse 2Immunoglobulin Light-chain Amyloidosis 2Endometrial Neoplasms 2

Interventions

Fluorouracil 26Radiotherapy 17Mitomycin 17Cisplatin 12Capecitabine 12pembrolizumab 10Cyclophosphamide 9Radiation 8Paclitaxel 8fludarabine 7Specimen Handling 7Nivolumab 7Carboplatin 7Magnetic Resonance Spectroscopy 6Cetuximab 6Biopsy 6Papillomavirus Vaccines 5Drug Therapy 5dehydroftorafur 4aldesleukin 4Vaccines 4Radiotherapy, Intensity-Modulated 4Irinotecan 4Watchful Waiting 3Taxes 3Oxaliplatin 3Observation 3Light Coagulation 3Ipilimumab 3Interleukin-2 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Anus Neoplasms × Phantoms, Imaging × Clear all
NCT03233711 2026-05-29

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡